HK1040237B - 作為藥劑的稠和多環氨基酸 - Google Patents

作為藥劑的稠和多環氨基酸

Info

Publication number
HK1040237B
HK1040237B HK02101978.2A HK02101978A HK1040237B HK 1040237 B HK1040237 B HK 1040237B HK 02101978 A HK02101978 A HK 02101978A HK 1040237 B HK1040237 B HK 1040237B
Authority
HK
Hong Kong
Prior art keywords
amino acids
pharmaceutical agents
fused polycyclic
polycyclic amino
fused
Prior art date
Application number
HK02101978.2A
Other languages
English (en)
Other versions
HK1040237A1 (en
Inventor
Stephen Bryans Justin
Christopher Horwell David
Osborne Simon
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of HK1040237A1 publication Critical patent/HK1040237A1/xx
Publication of HK1040237B publication Critical patent/HK1040237B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/34—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/58—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/02—Ortho- or ortho- and peri-condensed systems
    • C07C2603/04—Ortho- or ortho- and peri-condensed systems containing three rings
    • C07C2603/06—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members
    • C07C2603/10—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings
    • C07C2603/12—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings only one five-membered ring
    • C07C2603/14—Benz[f]indenes; Hydrogenated benz[f]indenes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
HK02101978.2A 1999-05-26 2002-03-14 作為藥劑的稠和多環氨基酸 HK1040237B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13610099P 1999-05-26 1999-05-26
PCT/GB2000/001819 WO2000073259A1 (en) 1999-05-26 2000-05-12 Fused polycyclic amino acids as pharmaceutical agents

Publications (2)

Publication Number Publication Date
HK1040237A1 HK1040237A1 (en) 2002-05-31
HK1040237B true HK1040237B (zh) 2004-12-31

Family

ID=22471297

Family Applications (1)

Application Number Title Priority Date Filing Date
HK02101978.2A HK1040237B (zh) 1999-05-26 2002-03-14 作為藥劑的稠和多環氨基酸

Country Status (13)

Country Link
EP (1) EP1180094B1 (zh)
JP (1) JP2003500466A (zh)
AT (1) ATE272048T1 (zh)
AU (1) AU4770400A (zh)
BR (1) BR0010961A (zh)
CA (1) CA2373210A1 (zh)
DE (1) DE60012508T2 (zh)
DK (1) DK1180094T3 (zh)
ES (1) ES2228524T3 (zh)
HK (1) HK1040237B (zh)
MX (1) MXPA01011955A (zh)
PT (1) PT1180094E (zh)
WO (1) WO2000073259A1 (zh)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0313432A (pt) * 2002-08-15 2005-07-12 Pfizer Uso terapêutico de aminoácidos bicìclicos ou tricìclicos fundidos
EP1820502A1 (en) 2006-02-10 2007-08-22 Laboratorios Del Dr. Esteve, S.A. Active substance combination comprising azolylcarbinol compounds
EP2116539A1 (en) 2008-04-25 2009-11-11 Laboratorios Del. Dr. Esteve, S.A. 1-aryl-3-aminoalkoxy-pyrazoles as sigma ligands enhancing analgesic effects of opioids and attenuating the dependency thereof
EP2353598A1 (en) 2010-02-04 2011-08-10 Laboratorios Del. Dr. Esteve, S.A. Sigma ligands for use in the prevention and/or treatment of postoperative pain
EP2353591A1 (en) 2010-02-04 2011-08-10 Laboratorios Del. Dr. Esteve, S.A. Sigma ligands for potentiating the analgesic effect of opioids and opiates in post-operative pain and attenuating the dependency thereof
EP2388005A1 (en) 2010-05-21 2011-11-23 Laboratorios Del. Dr. Esteve, S.A. Sigma ligands for the prevention and/or treatment of emesis induced by chemotherapy or radiotherapy
EP2415471A1 (en) 2010-08-03 2012-02-08 Laboratorios Del. Dr. Esteve, S.A. Use of sigma ligands in opioid-induced hyperalgesia
EP2524694A1 (en) 2011-05-19 2012-11-21 Laboratorios Del. Dr. Esteve, S.A. Use of sigma ligands in diabetes type-2 associated pain
TW201607538A (zh) 2013-12-17 2016-03-01 以斯提夫博士實驗室股份有限公司 血清素－去甲腎上腺素再攝取抑制劑（ＳＮＲＩＳ）和σ受體配體組合物
MA39146A1 (fr) 2013-12-17 2017-11-30 Esteve Labor Dr Combinaisons de gabapentanoïdes et de ligands des récepteurs sigma

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2125980C1 (ru) * 1991-11-05 1999-02-10 Смитклайн Бичам Корпорейшн Антагонисты эндотелиновых рецепторов, фармкомпозиция, способ их получения, способ подавления эндотелиновых рецепторов
US6153650A (en) * 1996-10-23 2000-11-28 Warner-Lambert Company Substituted gamma aminobutyric acids as pharmaceutical agents
CN1303059C (zh) * 1997-10-27 2007-03-07 沃尼尔·朗伯公司 作为药物的环状氨基酸及其衍生物

Also Published As

Publication number Publication date
DK1180094T3 (da) 2004-11-01
EP1180094A1 (en) 2002-02-20
DE60012508D1 (de) 2004-09-02
JP2003500466A (ja) 2003-01-07
WO2000073259A1 (en) 2000-12-07
CA2373210A1 (en) 2000-12-07
BR0010961A (pt) 2002-03-26
MXPA01011955A (es) 2003-09-04
AU4770400A (en) 2000-12-18
EP1180094B1 (en) 2004-07-28
DE60012508T2 (de) 2005-06-23
ES2228524T3 (es) 2005-04-16
PT1180094E (pt) 2004-10-29
HK1040237A1 (en) 2002-05-31
ATE272048T1 (de) 2004-08-15

Similar Documents

Publication Publication Date Title
GB9914486D0 (en) Medicaments
SE9904505D0 (sv) Novel compounds
IL139825A0 (en) Novel cyclosporins
HUP9902136A3 (en) Novel substituted cyclic amino acid derivatives use as pharmaceutical agents
GB0018828D0 (en) Alkyl Amino Acid Derivatives useful as pharmaceutical agents
HRP20020428B1 (en) Bicyclic amino acids as pharmaceutical agents
PL350456A1 (en) N−cyanomethylamides as protease inhibitors
FI950309A0 (fi) Proliiniamidijohdannaisia
IL133627A0 (en) Antithrombotic agents
BG106586A (en) Pyrazolopyramidines as therapeutic agents
MXPA02007942A (es) Derivados de pirrolopirimidinona, procesos de preparacion y uso.
AU2001260455A1 (en) Cyclic amino acid derivatives useful as pharmaceutical agents
MX9706605A (es) Derivados de indol como antagonistas de los aminoacidos exitadores.
HK1040237A1 (en) Fused polycyclic amino acids as pharmaceutical agents.
EP1019047A4 (en) ANTITHROMBOTIC AGENTS
TW252979B (zh)
NZ515685A (en) Use of riluzole for the treatment of multiple sclerosis
EP1027051A4 (en) ANTITHROMBOTIC AGENTS
SE9800865D0 (sv) New Process
IL134194A0 (en) Streptogramines, their preparation and compositions containing them
SE9901340D0 (sv) Novel process
DE69824410D1 (en) Antithrombosemittel
HUP9902307A2 (hu) Új, áthidalt gyűrűs aminosavak, előállításuk és intermedierjeik
SE9901338D0 (sv) Novel process
EP1452522A3 (en) Novel compounds and compositions as protease inhibitors

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20080512